Long term trial of ketotifen in bronchial asthma.
Ketotifen in a dose of 1 mg p.o. q 12 h was compared with placebo in a double-blind, twelve month parallel group trial in 17 randomly selected patients with bronchial asthma. Among 13 patients treated with ketotifen, nine have been classified as responders and four as non-responders. Responders were young and teenaged individuals, athletically oriented, with moderate asthma. It is our impression that ketotifen offers a new therapeutic dimension in the prophylaxis of bronchial asthma.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000403:Airway Resistance / Q000187:drug effects; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology; D002648:Child; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D005260:Female; D005541:Forced Expiratory Volume; D006801:Humans; D007665:Ketotifen / Q000494:pharmacology / Q000627:therapeutic use*; D008134:Long-Term Care; D008297:Male; D008875:Middle Aged
D007665:Ketotifen